Why Is Doximity (DOCS) Stock Down -23% Today?
Key Takeaways
- DOCS shares are down approximately 23% in premarket trading on May 14, 2026, following a post-earnings selloff that began after the close on May 13
- Primary catalyst: Doximity issued fiscal year 2027 annual revenue guidance of $664M–$676M, falling well short of the Wall Street consensus near $697.4 million
- Secondary driver: Q4 FY2026 adjusted EPS of $0.26 per diluted share declined sharply from $0.38 in the prior-year period and missed analyst estimates
- Management described fiscal 2027 as an "AI investment year," signaling accelerating spending that is expected to weigh on near-term profitability
- Multiple analyst firms responded with downgrades and steep price target cuts, intensifying selling pressure
- Traders are watching whether Doximity's pharma advertising revenue rebounds in the back half of fiscal 2027 and whether AI product investments can translate into measurable monetization
Opening Summary
Doximity, Inc. (DOCS) is the leading digital platform for U.S. medical professionals, connecting over 80% of the country's licensed physicians through tools spanning clinical communications, telehealth, and pharmaceutical advertising. The company reported its fiscal fourth-quarter and full-year 2026 results after the close on May 13, 2026. In premarket trading on May 14, DOCS shares are down approximately 23% from the prior closing price of $26.45, placing the stock near $20.37. While Doximity's Q4 revenue edged above guidance, the forward revenue outlook for fiscal 2027 came in sharply below consensus, and the year-over-year drop in adjusted earnings per share amplified investor concern.
Earnings Miss and Guidance Shortfall
Doximity posted Q4 FY2026 revenue of $145.4 million, modestly above the $143.91 million analyst consensus and above the high end of its own guidance. However, the headline miss that drove the selloff was on the earnings line: adjusted EPS of $0.26 per diluted share for the quarter came in below estimates and represented a steep decline from the $0.38 per diluted share posted in Q4 FY2025. For the full fiscal year, revenue reached $644.9 million, up 13% year-over-year, with adjusted net income of $302.7 million. Despite the revenue beat, the forward-looking numbers dominated market sentiment.
Weak Fiscal 2027 Outlook
The most damaging element of Doximity's earnings release was the fiscal 2027 annual revenue guidance of $664 million to $676 million — a range that fell more than $20 million short of the approximately $697.4 million analysts had expected. For Q1 FY2027 specifically, DOCS guided revenue of $151 million to $152 million, again below the $153.7 million consensus estimate. The implied growth rate of just 3%–4% in the near term stands in stark contrast to the double-digit growth trajectory Wall Street had anticipated heading into this report. Management cited pharmaceutical advertising market softness and ongoing budget uncertainty among key clients as contributing factors to the tempered outlook.
AI Investment Year and Margin Pressure
Adding to investor unease, Doximity's management framed fiscal 2027 as an "AI investment year," explicitly signaling that capital expenditure and operating expenses will rise to support artificial intelligence product development. While the company highlighted new AI-driven features aimed at increasing platform value for physicians and pharma advertisers, the market interpreted this as near-term margin compression rather than a near-term revenue driver. Profitability concerns were amplified by the fact that adjusted EPS for Q4 had already contracted significantly year-over-year, suggesting that incremental AI spending will arrive before incremental AI-driven revenue materializes.
Analyst Downgrades and Price Target Cuts
The earnings report triggered a wave of analyst reactions that further pressured DOCS shares in premarket. Jefferies downgraded the stock to Hold from Buy and slashed its price target from $51 to $19, citing uncertainty in the pharmaceutical advertising environment. Baird similarly downgraded Doximity to Neutral from Outperform, cutting its target from $40 to $18 and expressing concern about the timeline for a recovery in growth. Goldman Sachs maintained its Neutral rating but lowered its price target from $34 to $28. Collectively, these revisions reflect a significant reset in valuation expectations, with several analysts citing the combination of decelerating growth, rising investment costs, and limited visibility on pharma ad spend as key risk factors.
Market Context and Trading Activity
The premarket decline in DOCS is occurring on sharply elevated volume compared to typical pre-open sessions, consistent with a high-conviction post-earnings reaction. The move continues a painful pattern for Doximity shareholders: the stock had already experienced a roughly 34% single-day drop in February 2026 following Q3 results, and was down approximately 47% year-to-date before today's premarket session. From a technical standpoint, the decline pushes DOCS toward multi-year lows, eroding several key support levels that had held during prior bouts of selling. Peers in the digital health and healthcare technology space may also face sympathy pressure, as Doximity's guidance miss signals ongoing headwinds across pharma-facing digital platforms.
Trending AI Robots
For traders navigating high-volatility situations like today's sharp move in DOCS, Tickeron's Trending AI Robots page offers a curated selection of the best-performing AI trading bots active under current market conditions. Tickeron operates hundreds of AI-driven trading agents covering thousands of tickers and strategies, but only those demonstrating the strongest recent performance metrics are spotlighted in this Trending section. The featured bots vary widely by strategy type, traded symbols, holding timeframe, and risk profile — spanning momentum plays, mean-reversion setups, sector rotations, and more. Investors and active traders seeking a systematic, data-driven edge can explore Trending AI Robots to identify bots aligned with their individual trading goals and risk tolerance.
What Comes Next for DOCS
The next major milestone for DOCS will be the fiscal Q1 FY2027 earnings report, expected in early August 2026, which will reveal whether management's conservative $151M–$152M revenue guidance proves to be the floor or an accurate baseline. The primary variable driving sentiment will be the pace of pharmaceutical advertising budget recovery — any visible uptick in pharma marketing spend would be a meaningful positive catalyst. Analysts will also be closely monitoring the pace at which Doximity's AI product investments begin to show up as incremental revenue rather than incremental cost. Broader macroeconomic factors, including federal pharmaceutical pricing policy and healthcare regulatory developments, remain relevant overhangs that could either accelerate or further delay advertising recovery. Any revision to guidance — upward or downward — from management at upcoming investor events could serve as a near-term inflection point for the stock.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DOCS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for DOCS turned positive on June 01, 2026. Looking at past instances where DOCS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DOCS's RSI Indicator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where DOCS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 23, 2026. You may want to consider a long position or call options on DOCS as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DOCS advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day moving average for DOCS crossed bearishly below the 50-day moving average on May 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DOCS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. DOCS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.860) is normal, around the industry mean (7.368). P/E Ratio (20.480) is within average values for comparable stocks, (49.965). Projected Growth (PEG Ratio) (0.590) is also within normal values, averaging (1.153). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (6.196) is also within normal values, averaging (5.648).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DOCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement